Piper Sandler Increases Aquestive Therapeutics (NASDAQ:AQST) Price Target to $8.00

Aquestive Therapeutics (NASDAQ:AQST) had its target price lifted by equities research analysts at Piper Sandler from $5.00 to $8.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s target price points to a potential upside of 32.45% from the company’s current price.

Other equities research analysts also recently issued reports about the company. Oppenheimer raised their target price on Aquestive Therapeutics from $7.00 to $8.00 and gave the company an “outperform” rating in a report on Monday, September 8th. Citigroup reaffirmed an “outperform” rating on shares of Aquestive Therapeutics in a research report on Thursday, October 9th. Zacks Research raised shares of Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday, October 8th. Finally, Lifesci Capital upgraded Aquestive Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 3rd. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Aquestive Therapeutics has a consensus rating of “Buy” and an average price target of $10.00.

Aquestive Therapeutics Stock Performance

AQST opened at $6.04 on Friday. Aquestive Therapeutics has a 1 year low of $2.12 and a 1 year high of $7.55. The firm has a 50 day moving average price of $5.88 and a 200 day moving average price of $4.28. The company has a market cap of $736.88 million, a PE ratio of -8.51 and a beta of 1.79.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The company had revenue of $12.81 million for the quarter, compared to analyst estimates of $12.94 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Insider Transactions at Aquestive Therapeutics

In related news, insider Carl N. Kraus sold 20,272 shares of Aquestive Therapeutics stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $7.00, for a total transaction of $141,904.00. Following the transaction, the insider directly owned 282,475 shares of the company’s stock, valued at $1,977,325. The trade was a 6.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Daniel Barber sold 91,343 shares of the business’s stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $6.03, for a total transaction of $550,798.29. Following the completion of the sale, the chief executive officer owned 923,430 shares in the company, valued at $5,568,282.90. The trade was a 9.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 276,770 shares of company stock worth $1,692,203. Corporate insiders own 8.35% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets increased its holdings in shares of Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock valued at $31,000 after purchasing an additional 4,134 shares during the period. Summit Wealth & Retirement Planning Inc. bought a new position in shares of Aquestive Therapeutics in the first quarter worth about $29,000. USAdvisors Wealth Management LLC acquired a new stake in shares of Aquestive Therapeutics in the second quarter worth $33,000. Modern Wealth Management LLC bought a new position in shares of Aquestive Therapeutics during the 2nd quarter worth about $33,000. Finally, Cox Capital Mgt LLC bought a new stake in shares of Aquestive Therapeutics in the 3rd quarter worth approximately $59,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.